10 June 2024



Eden Research Plc

("Eden" or "Company")

Appointment of Global Commercial Lead

Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technologies for use in the global crop protection, animal health and consumer products industries, is delighted to announce the appointment of Humair Tariq as the Company's new Global Commercial Lead. Humair assumes his new role with immediate effect.

Humair has considerable experience in the crop protection industry, most recently working for Syngenta as Portfolio Manager for biologicals, seed treatment and insect control. Prior to that, he held a series of global and regional positions with Syngenta in both Basel and Pakistan. Humair holds an MBA degree with a focus on marketing.

Humair will be responsible for leading Eden's commercial efforts, fostering the Company's existing partnerships, developing new relationships with potential partners, and driving revenue growth through both the expansion of our existing business and the pursuit of new opportunities.

Sean Smith, Chief Executive Officer of Eden Research, commented:

"We are pleased to welcome Humair Tariq to the Eden team as Global Commercial Lead with immediate effect. Humair has spent the majority of his career working within the food value chain and brings with him invaluable industry experience and expertise. He joins a small but growing commercial team at Eden, focused on growth and the creation of long-term value for our partners and shareholders. Humair's appointment is a demonstration of our intent to add to our team's resources and capabilities, supported by our stronger balance sheet following last Summer's fundraise and our increasing revenue streams as we continue to grow the company organically across various fronts. We look forward to his contributions and the opportunities that lie ahead."

For further information contact:

Eden Research plc Sean Smith Alex Abrey

www.edenresearch.com 01285 359 555

020 7220 0500

Cavendish Capital Markets Limited (Nominated advisor and broker)

Giles Balleny / George Lawson (corporate finance) Charlie Combe (corporate broking) Michael Johnson (sales)

Hawthorn Advisors (Financial PR)

Victoria Ainsworth

eden@hawthornadvisors.com

Notes to Editors:

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has three products currently on the market:

Based on plant-derived active ingredients, **Mevalone**[®] is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops. It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally.

CedrozTM is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally. Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally.

Eden's seed treatment product, **Ecovelex** was developed to safely tackle crop destruction caused by birds - a major cause of losses in maize and other crops. Ecovelex works by creating an unpleasant taste or odour that repels birds, leaving the seeds safely intact and the birds unaffected and free to find alternative food sources. The product is based on Eden's plant-derived chemistry, registered in the EU, U.S. and elsewhere, and formulated using Eden's Sustaine® microencapsulation system.

Eden's **Sustaine[®]** encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-

of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange **Green Economy Mark** in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services. For more information about Eden, please visit: <u>www.edenresearch.com</u>.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact <u>ms@seg.com</u> or visit <u>www.ms.com</u>.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

END

NRAFIFEDRAIILIS